Walter Rayford, PhD
Urology · Memphis, TNNPI 1821103151
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,241 of the $26,028 with a category attached, or 70.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 12.0%.
Across 743 payments — averaging $35.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Dendreon Pharmaceuticals LLC$3K
- Pfizer$2K
- Coloplast$2K
- Boston Scientific$2K
- Teleflex LLC$1K
- plus $13K from 54 others
Across 20 payments — averaging $11,930 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Myriad Genetic Laboratories, Inc.$224K
- Dendreon Pharmaceuticals LLC$15K
What the payments were for
- Speaking & faculty fees$3,15012%
- Travel & lodging$3,96915%
- Food & beverage$18,24170%
- Education$6452%
- Gifts$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,888
- PROVENGE$2,074
- AquaBeam Robotic System$1,097
- UroLift$782
- Barrigel$337
- Bulkamid$256
- LYNPARZA$231
- Nanoknife$150
- UroCuff$146
- UroLift ATC System$136
- Axonics$135
- Prolaris$132
- LithoVue$123
- TITAN$118
- ORGOVYX$115
- XIAFLEX$113
- Auryon Laser System 100-120 Vac$108
- Tulsa-Pro$107
- Axumin$104
- LIBTAYO$103
How this compares
$26,028 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 392 | $5,371,506 |
| NubeqaDarolutamide | 85 | $994,890 |
| ErleadaApalutamide | 39 | $558,661 |
| OrgovyxRelugolix | 176 | $455,541 |
| GemtesaVibegron | 279 | $213,196 |
| MyrbetriqMirabegron | 192 | $151,170 |
| Abiraterone Acetate | 46 | $116,776 |
| XgevaDenosumab | 12 | $37,145 |
| Tamsulosin Hcl | 1,457 | $24,157 |
| Testosterone | 41 | $16,430 |
| Oxybutynin Chloride ErOxybutynin Chloride | 334 | $12,027 |
| XyostedTestosterone Enanthate | 11 | $6,685 |
| Finasteride | 527 | $6,548 |
| Solifenacin Succinate | 98 | $5,792 |
| Silodosin | 40 | $4,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,246 | $5,522,675584 claims |
| BayerNubeqa | $138 | $994,89085 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $1,294 | $668,737455 claims |
| Johnson & JohnsonErleada | $637 | $558,66139 claims |
| AmgenXgeva | $109 | $37,14512 claims |
| Antares Pharma, Inc.Xyosted | $159 | $6,68511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.
Other urology in Memphis
- David GubinMemphis$1M
- Mark GreenbergerMemphis$249K
- Mark SaslawskyMemphis$33K
- L KnollNashville$2.1M
- Gautam JayramNashville$1M
- David MorrisHendersonville$871K
- Roger DmochowskiNashville$763K
- Paul EberGermantown$476K
- Ashley TapscottNashville$425K
- Raoul ConcepcionNashville$339K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.